Federated Hermes Inc. Sells 320,757 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Federated Hermes Inc. reduced its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 19.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,306,936 shares of the biotechnology company's stock after selling 320,757 shares during the period. Federated Hermes Inc. owned 0.55% of ADMA Biologics worth $22,414,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after buying an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after acquiring an additional 700 shares during the period. Mutual of America Capital Management LLC grew its position in shares of ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 751 shares in the last quarter. Maryland State Retirement & Pension System raised its stake in shares of ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after purchasing an additional 897 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $1.50 on Monday, reaching $20.90. The company's stock had a trading volume of 1,384,079 shares, compared to its average volume of 3,554,927. The company has a market capitalization of $4.94 billion, a P/E ratio of 74.64 and a beta of 0.53. ADMA Biologics, Inc. has a 12-month low of $5.91 and a 12-month high of $23.64. The stock's 50 day simple moving average is $17.78 and its 200-day simple moving average is $18.15. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.